Nuvation Bio wins FDA fast-track status for safusidenib in IDH1-mutant glioma

• Nuvation Bio received FDA Fast Track designation for safusidenib in IDH1-mutant glioma, a step that could speed development and review.
• Updated Phase 2 J201 results were already presented, showing durable patient responses with a favorable long-term safety profile.
• A pivotal Phase 3 SIGMA trial is enrolling, positioning the program for a potential expedited regulatory filing if outcomes hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608200800PR_NEWS_USPR_____NY29893) on August 20, 2026, and is solely responsible for the information contained therein.